Parkinson’s drug opicapone launches in the UK and Germany

News

Author: Parkinson's Life editorsPublished: 21 October 2016

Prep: Cook: Serves:

Parkinson’s drug opicapone is now available in the UK and Germany as a once-daily dose, following authorisation by the European Commission (EC).

Produced by BIAL under the brand name ‘Ongentys’, opicapone is in a class of drugs known as ‘COMT inhibitors’, which can extend the therapeutic effects of levodopa.

It is intended for use by Parkinson’s patients who experience end-of-dose motor complications such as “wearing-off” from long-term levodopa use.

Professor Andrew Lees, Professor of Neurology, University College London, said: “There is still an unmet medical need for effective new therapeutic options for Parkinson’s disease. Opicapone will provide clinicians in UK with a COMT inhibitor, with the convenience of once-daily dosing.”

The results of a phase III clinical trial involving 600 patients across in Europe was published in the ‘The Lancet Neurology in December 2015’, and the drug was approved for use by the EC in July 2016.

Last Month

Next Month

Go Back

Share this story

Comments

Episodes

Podcast: Everyday life after DBS surgery

Our second episode on deep brain stimulation for Parkinson’s disease

Debate: are people with Parkinson’s “sick”? (Part One)

The first in a two-part series

Special reports

STEP – The lived experience of Parkinson’s disease

STEP™ hopes to give a voice to people living with Parkinson’s

Study finds just six minutes of daily exercise might delay onset of Parkinson’s disease

Regular exercise is a common therapeutic strategy for people with Parkinson’s. Now, a study from New Zealand has suggested that daily physical activity might even delay the onset of this condition. Published in ‘The Physiological Society’, the study focused on a protein called brain-derived neurotrophic factor (BDNF) – which has previously been shown to boost cognitive performance. The researchers assessed the impact of fasting and physical activity on BDNF production in 12 people aged 18 to 56. The tests involved fasting and completing exercises of varying intensity, such as cycling for six minutes, as well as combinations of both fasting and physical activity. The results showed that brief, intense exercise was the best option for increasing the production of BDNF – with the protein increasing by a factor of four to five times compared to light exercise or fasting. Because BDNF can protect the brain from cognitive decline, the findings could…

Machine learning may help predict risk of freezing of gait in Parkinson’s disease

Difficulty taking steps forward, often referred to as the freezing of gait (FOG), is a common symptom experienced by people with Parkinson’s and one that can be difficult to predict. China-based researchers suggest that machine learning – artificial intelligence (AI) that uses algorithms to analyse data – could help predict the risk of freezing of gait developing in the early stages of the condition. Their study, published in ‘npj Parkinson’s Disease’, gave laboratory and clinical data to a machine learning model brain. This information was collected from 158 adults with untreated early-stage Parkinson’s and 73 healthy adults over a five-year period. They found that the risk of FOG could be predicted with an accuracy rate of up to 78%. The study authors suggested that machine learning methods “have the potential to help predict future FOG in patients with early Parkinson’s at an individual level”.

Long-term exposure to air pollution could impact Parkinson’s disease mortality risk

New research has suggested that long-term exposure to air pollutants could increase the risk of death from Parkinson’s. A team of European researchers conducted the study, published in the journal ‘Environment International’, as part of the Effects of Low-Level Air Pollution: A Study in Europe (ELAPSE) project – a Europe-wide initiative looking at the effects of low air pollution levels on people’s health. The researchers used ELAPSE’s datasets to analyse figures for over 200,000 adults from six European countries. They also looked at air pollution models, estimating the concentrations of air pollutants in these countries to explore the link between pollution exposure and deaths from Parkinson’s. The results suggest that long-term exposure to PM2.5 particles at high levels was associated with a 25% higher risk of death from the condition, and the authors of the study added that the research “adds strong evidence in support of an association between air…

All fields required